The Economics of Genomic Medicine Workshop Summary (2013) / Chapter Skim
Currently Skimming:
Appendix B: Speaker Biographical Sketches
Appendix B: Speaker Biographical Sketches
Pages 87-98
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 87... ...
Dr. Armstrong has completed fellowship training in health services research and clinical epidemiology, as well as clinical training in genetic counseling and testing for breast cancer susceptibility.
|
From page 88... ...
He has studied genomic imprinting as it relates to Prader-Willi and Angelman syndromes, including identification of the causative role of the UBE3A gene in Angelman syndrome and of the importance of the snoRNA genes in the pathogenesis of Prader-Willi syndrome. In 2004 Beaudet and a BCM team of investigators were the first in the United States to introduce array comparative genomic hybridization into the clinical lab, and they have gone on to play a leadership role in the transformative impact of this technology on clinical g enetics.
|
From page 89... ...
Paul R Billings, M.D., Ph.D., is a board-certified internist and clinical geneticist who serves as chief medical officer of Life Technologies Corporation, where he seeks to improve patient care through expanding the use of medically relevant genomic technologies in clinical settings.
|
From page 90... ...
At the University of Washington, he has been the lead faculty for the WWAMI Underserved Pathway, medical director for the Washington State Patient-Centered Medical Home Collaborative, and a researcher in the Rural Health Research Center. He is the medical director for the Washington State employees' health plan and served as the chair of the American Academy of Family Physicians' Subcommittee on Genomics.
|
From page 91... ...
Eck, M.D., Ph.D., is vice president and global head of oncology medical science at Astellas Pharma Global Development. He is directly responsible for the oversight of oncology drug development plans.
|
From page 92... ...
For the Center for Jewish Genetics, Ms. Gilats provides education regarding Jewish genetic disorders and hereditary cancers to community groups and counsels individuals and couples about carrier testing.
|
From page 93... ...
Since his initial diagnosis, Mr. Heimler has been an active lung cancer advocate, providing inspiration and advice to newly diagnosed lung cancer patients and raising awareness among the media, politicians, and the general public so that he and fellow lung cancer survivors may look forward to celebrating many more birthdays.
|
From page 94... ...
Kenneth Offit, M.D., is chief of the clinical genetics service at Memorial Sloan-Kettering Cancer Center and a professor of medicine and public health at the Weill College of Medicine at Cornell University. His research group first described and characterized the most common BRCA2 mutation associated with breast and ovarian cancer, was among the first to measure prospectively the impact of preventive ovarian surgery in individuals carrying BRCA mutations, and performed the first genome-wide association study of BRCA2 breast cancer.
|
From page 95... ...
Scott Ramsey, M.D., Ph.D., is a full member in the Cancer Prevention Program at the Fred Hutchinson Cancer Research Center, where he directs the Research and Economic Assessment in Cancer and Healthcare group, a multidisciplinary team devoted to clinical and economic evaluations of new and existing cancer prevention, screening, and treatment technologies. He is also a professor in the School of Medicine, School of Pharmacy, and Institute for Public Health Genetics at the University of Washington.
|
From page 96... ...
His research is funded through grants from the Centers for Disease Control and Prevention, National Cancer Institute, National Human Genome Research Institute, and National Institute for General Medical Sciences. He has worked extensively with the Academy of Managed Care Pharmacy to develop guidelines and train decision makers in the practical application of cost-effectiveness models.
|
From page 97... ...
From 1989 to 2000 he worked for Roche Molecular Systems, a diagnostics division of Hoffmann–La Roche. As senior vice president of research and development, he was responsible for La Roche's research and development on PCR-based tests on the Cobas instrument systems for diagnosing infectious diseases, genetic diseases, and cancer; for screening the blood supply for human immunodeficiency virus, hepatitis C virus, and hepatitis B virus; and for developing new applications of PCR for basic research, forensics, and the human genome project.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.